MBB Public Markets I LLC Invests $307,000 in Agilent Technologies, Inc. $A

Key Points

• MBB Public Markets I LLC has invested approximately $307,000 in Agilent Technologies, Inc., acquiring 2,622 shares during the first quarter.
• Several institutional investors, including Valeo Financial Advisors LLC and Western Pacific Wealth Management LP, have increased their stakes in Agilent Technologies by various percentages during the same period.
• Agilent Technologies recently reported earnings of $1.37 per share, meeting analysts' consensus estimates, with a 10.1% year-over-year increase in quarterly revenue.

MBB Public Markets I LLC purchased a new stake in Agilent Technologies, Inc. (NYSE:A - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,622 shares of the medical research company's stock, valued at approximately $307,000.

Several other institutional investors have also bought and sold shares of the stock. Valeo Financial Advisors LLC boosted its stake in Agilent Technologies by 3.0% in the 1st quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company's stock valued at $403,000 after buying an additional 102 shares in the last quarter. Cary Street Partners Financial LLC boosted its stake in Agilent Technologies by 2.9% in the 1st quarter. Cary Street Partners Financial LLC now owns 3,688 shares of the medical research company's stock valued at $431,000 after buying an additional 103 shares in the last quarter. Western Pacific Wealth Management LP boosted its stake in Agilent Technologies by 15.2% in the 1st quarter. Western Pacific Wealth Management LP now owns 873 shares of the medical research company's stock valued at $102,000 after buying an additional 115 shares in the last quarter. Bartlett & CO. Wealth Management LLC boosted its stake in Agilent Technologies by 5.1% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,406 shares of the medical research company's stock valued at $281,000 after buying an additional 116 shares in the last quarter. Finally, Brighton Jones LLC boosted its stake in Agilent Technologies by 2.6% in the 1st quarter. Brighton Jones LLC now owns 4,784 shares of the medical research company's stock valued at $560,000 after buying an additional 121 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Wall Street Zen lowered Agilent Technologies from a "buy" rating to a "hold" rating in a research note on Friday, September 5th. TD Cowen boosted their price target on Agilent Technologies to $150.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Wells Fargo & Company boosted their price objective on Agilent Technologies from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. JPMorgan Chase & Co. reduced their price objective on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a research note on Thursday, May 29th. Finally, Barclays reissued an "equal weight" rating and issued a $125.00 price objective on shares of Agilent Technologies in a research note on Friday, August 29th. Six equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $139.25.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $124.24 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The firm has a market cap of $35.22 billion, a P/E ratio of 29.16, a P/E/G ratio of 3.93 and a beta of 1.24. The business's fifty day moving average is $119.61 and its two-hundred day moving average is $116.13. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting analysts' consensus estimates of $1.37. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm's quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.